StockIQpro
NASDAQ:GLUE

Monte Rosa Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Monte Rosa Therapeutics, Inc.'s revenue grew 63.5% in fiscal 2025 to $123.7M while operating margin rose to −43.8%. Free cash flow was −$27.5M, −22.2% of revenue, and the diluted share count rose 12.4%.Summary generated from Monte Rosa Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$123.7M
Revenue growth+63.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−43.8%
Net margin−31.2%
ROICn/a
Return on equity−16.9%
Debt / equityn/a
Free cash flow−$27.5M
FCF margin−22.2%
Share count change+12.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a076124
Operating income−73−112−143−81−54
Net income−74−109−135−73−39
Free cash flow−69−105−6338−27

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)